Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 3

Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients

Authors Dalal P, Shah, Chhara, Gallon L

Published 4 August 2010 Volume 2010:3 Pages 107—115

DOI https://doi.org/10.2147/IJNRD.S7044

Review by Single-blind

Peer reviewer comments 3


P Dalal1, G Shah1, D Chhabra2, Lorenzo Gallon2

1Department of Medicine, Mount Sinai Hospital, Chicago; 2Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

Introduction: Several new medications are now available for immunosuppression in the kidney transplant field. Tacrolimus and mycophenolate mofetil were first introduced for ­immunosuppression in renal transplantation in the mid 1990s. Since then, the combination of tacrolimus and mycophenolate mofetil has been evaluated in numerous clinical trials. The outcomes of these trials have varied due to differences in induction and/or maintenance therapy, drug dosing and monitoring protocols, and study design. The aim of this review is to analyze the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil combination therapy in renal transplantation.

Keywords: mycophenolate mofetil, tacrolimus, kidney transplantation, immunosuppression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]